ArticleOncology letters2012
Serum amyloid A: A new potential serum marker correlated with the stage of breast cancer.
Article in Oncology letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Article
- Proteomics analysis reveals elevated RAB21 in serum-derived extracellular vesicles from patients with follicular thyroid carcinoma.Oncology letters · 2025Article
- Inflammation and Tumor Progression: The Differential Impact of SAA in Breast Cancer Models.Biology · 2024Article
- A functional role for Serum Amyloid A in the molecular regulation of autophagy in breast cancer.Frontiers in oncology · 2022Article
- Adaptation of Microarray Assay for Serum Amyloid a Analysis in Human Serum.Molecular biology · 2022Article
- Protein Corona Gold Nanoparticles Fingerprinting Reveals a Profile of Blood Coagulation Proteins in the Serum of HER2-Overexpressing Breast Cancer Patients.International journal of molecular sciences · 2020Article
- Serum amyloid A predisposes inflammatory tumor microenvironment in triple negative breast cancer.Oncotarget · 2019Article
- Amyloidosis and the risk of cancer: a nationwide population-based study.International journal of clinical oncology · 2015Article
- Increased concentrations of Serum amyloid A in dogs with sepsis caused by pyometra.BMC veterinary research · 2014Article
- Circulating levels and clinical implications of epithelial membrane antigen and cytokeratin-1 in women with breast cancer: can their ratio improve the results?Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- A review of the application of inflammatory biomarkers in epidemiologic cancer research.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Review
- Serum amyloid A promotes invasion of feline mammary carcinoma cells.The Journal of veterinary medical science · 2014Article
- Plasma proteomics analysis of tamoxifen resistance in breast cancer.Medical oncology (Northwood, London, England) · 2013Article
- Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment.Breast cancer (Dove Medical Press) · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies reported that serum amyloid A (SAA) is elevated in patients with tumors, including breast cancer, compared to healthy controls. In addition, the levels of SAA increase gradually with tumor progression. In this study, we investigated the blood SAA level of breast cancer patients, and evaluated its potential as a serum biomarker for the early diagnosis of breast cancer and as a staging estimate. SAA protein was determined by enzyme-linked immunosorbent assay in serum samples from 30 healthy women, 21 women with benign diseases and 118 breast cancer patients who were subdivided into 4 groups based on their clinical characteristics. SAA levels were not statistically different in stage I breast cancer patients compared with the healthy controls and benign breast disease patients. SAA concentrations had medians of 0.63 µg/ml in normal healthy women, 0.76 µg/ml in patients with benign disease (p>0.05) and 0.82 µg/ml in stage I breast cancer patients (p>0.05). By contrast, SAA values in stage Ⅱ, Ⅲ and Ⅳ patients had a significantly higher median compared to those of the healthy, benign breast diseases and stage I groups (p<0.05). Breast cancer patients with lymph node (LN) metastasis or distant metastasis were found to have significantly higher SAA concentrations than those without metastases. SAA is not a suitable marker for early breast cancer diagnosis, but its level is correlated with the stage of breast cancer. Thus, it may be a good candidate marker for the staging and prognosis of breast cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.